REGENXBIO Inc. - Common Stock (NQ:RGNX)

9.075 +0.325 (+3.71%)

Streaming Delayed Price Updated: 11:57 AM EST, Feb 27, 2026 Add to My Watchlist

Price and Volume

Volume	269,591
Open	8.620
Bid (Size)	9.050 (900)
Ask (Size)	9.100 (200)
Prev. Close	8.750
Today's Range	8.550 - 9.100
52wk Range	5.035 - 16.19
Shares Outstanding	43,466,186
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? ↗

Today 0:49 EST

Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121.

Via Stocktwits

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm

February 26, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Performance

YTD	-33.1%	-33.1%
1 Month	-32.3%	-32.3%
3 Month	-32.2%	-32.2%
6 Month	+0.7%	+0.7%
1 Year	+36.1%	+36.1%

More News

ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

February 26, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy ↗

February 26, 2026

Via Stocktwits

RGNX CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

February 25, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

February 24, 2026

From Pomerantz LLP

Via GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 24, 2026

From Schall Law

Via GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

February 23, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

February 20, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc.

February 20, 2026

From Robbins LLP

Via GlobeNewswire

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗

February 20, 2026

Via Stocktwits

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 20, 2026

From Schall Law

Via GlobeNewswire

REGENXBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against REGENXBIO Inc. and Encourages Investors to Contact the Firm

February 18, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

February 17, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

February 17, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

REGENXBIO Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – RGNX

February 17, 2026

From DJS Law Group

Via Business Wire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 16, 2026

From The Schall Law Firm

Via Business Wire

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the REGENXBIO, Inc. Securities Class Action Lawsuit

February 16, 2026

From Robbins LLP

Via Business Wire

Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

February 16, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

Via MarketMinute

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

Via The Motley Fool

Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street ↗

February 09, 2026

Via Stocktwits

Why Did RGNX Shares Plummet 19% After-Hours Today? ↗

February 09, 2026

Via Stocktwits

Monday's after hours session: top gainers and losers ↗

February 09, 2026

Via Chartmill

RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm

February 03, 2026

From The Schall Law Firm

Via Business Wire

Frequently Asked Questions

Is REGENXBIO Inc. - Common Stock publicly traded?

Yes, REGENXBIO Inc. - Common Stock is publicly traded.

What exchange does REGENXBIO Inc. - Common Stock trade on?

REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for REGENXBIO Inc. - Common Stock?

The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market

What is the current price of REGENXBIO Inc. - Common Stock?

The current price of REGENXBIO Inc. - Common Stock is 9.075

When was REGENXBIO Inc. - Common Stock last traded?

The last trade of REGENXBIO Inc. - Common Stock was at 02/27/26 11:57 AM ET

What is the market capitalization of REGENXBIO Inc. - Common Stock?

The market capitalization of REGENXBIO Inc. - Common Stock is 394.46M

How many shares of REGENXBIO Inc. - Common Stock are outstanding?

REGENXBIO Inc. - Common Stock has 394M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.